Cargando…
Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions
BACKGROUND: Studies have shown that industry-sponsored meta-analyses of drugs lack scientific rigour and have biased conclusions. However, these studies have been restricted to certain medical specialities. We compared all industry-supported meta-analyses of drug-drug comparisons with those without...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2553412/ https://www.ncbi.nlm.nih.gov/pubmed/18782430 http://dx.doi.org/10.1186/1471-2288-8-60 |
_version_ | 1782159502288617472 |
---|---|
author | Jørgensen, Anders W Maric, Katja L Tendal, Britta Faurschou, Annesofie Gøtzsche, Peter C |
author_facet | Jørgensen, Anders W Maric, Katja L Tendal, Britta Faurschou, Annesofie Gøtzsche, Peter C |
author_sort | Jørgensen, Anders W |
collection | PubMed |
description | BACKGROUND: Studies have shown that industry-sponsored meta-analyses of drugs lack scientific rigour and have biased conclusions. However, these studies have been restricted to certain medical specialities. We compared all industry-supported meta-analyses of drug-drug comparisons with those without industry support. METHODS: We searched PubMed for all meta-analyses that compared different drugs or classes of drugs published in 2004. Two authors assessed the meta-analyses and independently extracted data. We used a validated scale for judging the methodological quality and a binary scale for judging conclusions. We divided the meta-analyses according to the type of support in 3 categories: industry-supported, non-profit support or no support, and undeclared support. RESULTS: We included 39 meta-analyses. Ten had industry support, 18 non-profit or no support, and 11 undeclared support. On a 0–7 scale, the median quality score was 6 for meta-analyses with non-profit or no support and 2.5 for the industry-supported meta-analyses (P < 0.01). Compared with industry-supported meta-analyses, more meta-analyses with non-profit or no support avoided bias in the selection of studies (P = 0.01), more often stated the search methods used to find studies (P = 0.02), searched comprehensively (P < 0.01), reported criteria for assessing the validity of the studies (P = 0.02), used appropriate criteria (P = 0.04), described methods of allocation concealment (P = 0.05), described methods of blinding (P = 0.05), and described excluded patients (P = 0.08) and studies (P = 0.15). Forty percent of the industry-supported meta-analyses recommended the experimental drug without reservations, compared with 22% of the meta-analyses with non-profit or no support (P = 0.57). In a sensitivity analysis, we contacted the authors of the meta-analyses with undeclared support. Eight who replied that they had not received industry funding were added to those with non-profit or no support, and 3 who did not reply were added to those with industry support. This analysis did not change the results much. CONCLUSION: Transparency is essential for readers to make their own judgment about medical interventions guided by the results of meta-analyses. We found that industry-supported meta-analyses are less transparent than meta-analyses with non-profit support or no support. |
format | Text |
id | pubmed-2553412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-25534122008-09-26 Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions Jørgensen, Anders W Maric, Katja L Tendal, Britta Faurschou, Annesofie Gøtzsche, Peter C BMC Med Res Methodol Research Article BACKGROUND: Studies have shown that industry-sponsored meta-analyses of drugs lack scientific rigour and have biased conclusions. However, these studies have been restricted to certain medical specialities. We compared all industry-supported meta-analyses of drug-drug comparisons with those without industry support. METHODS: We searched PubMed for all meta-analyses that compared different drugs or classes of drugs published in 2004. Two authors assessed the meta-analyses and independently extracted data. We used a validated scale for judging the methodological quality and a binary scale for judging conclusions. We divided the meta-analyses according to the type of support in 3 categories: industry-supported, non-profit support or no support, and undeclared support. RESULTS: We included 39 meta-analyses. Ten had industry support, 18 non-profit or no support, and 11 undeclared support. On a 0–7 scale, the median quality score was 6 for meta-analyses with non-profit or no support and 2.5 for the industry-supported meta-analyses (P < 0.01). Compared with industry-supported meta-analyses, more meta-analyses with non-profit or no support avoided bias in the selection of studies (P = 0.01), more often stated the search methods used to find studies (P = 0.02), searched comprehensively (P < 0.01), reported criteria for assessing the validity of the studies (P = 0.02), used appropriate criteria (P = 0.04), described methods of allocation concealment (P = 0.05), described methods of blinding (P = 0.05), and described excluded patients (P = 0.08) and studies (P = 0.15). Forty percent of the industry-supported meta-analyses recommended the experimental drug without reservations, compared with 22% of the meta-analyses with non-profit or no support (P = 0.57). In a sensitivity analysis, we contacted the authors of the meta-analyses with undeclared support. Eight who replied that they had not received industry funding were added to those with non-profit or no support, and 3 who did not reply were added to those with industry support. This analysis did not change the results much. CONCLUSION: Transparency is essential for readers to make their own judgment about medical interventions guided by the results of meta-analyses. We found that industry-supported meta-analyses are less transparent than meta-analyses with non-profit support or no support. BioMed Central 2008-09-09 /pmc/articles/PMC2553412/ /pubmed/18782430 http://dx.doi.org/10.1186/1471-2288-8-60 Text en Copyright © 2008 Jørgensen et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Jørgensen, Anders W Maric, Katja L Tendal, Britta Faurschou, Annesofie Gøtzsche, Peter C Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions |
title | Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions |
title_full | Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions |
title_fullStr | Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions |
title_full_unstemmed | Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions |
title_short | Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: Differences in methodological quality and conclusions |
title_sort | industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2553412/ https://www.ncbi.nlm.nih.gov/pubmed/18782430 http://dx.doi.org/10.1186/1471-2288-8-60 |
work_keys_str_mv | AT jørgensenandersw industrysupportedmetaanalysescomparedwithmetaanalyseswithnonprofitornosupportdifferencesinmethodologicalqualityandconclusions AT marickatjal industrysupportedmetaanalysescomparedwithmetaanalyseswithnonprofitornosupportdifferencesinmethodologicalqualityandconclusions AT tendalbritta industrysupportedmetaanalysescomparedwithmetaanalyseswithnonprofitornosupportdifferencesinmethodologicalqualityandconclusions AT faurschouannesofie industrysupportedmetaanalysescomparedwithmetaanalyseswithnonprofitornosupportdifferencesinmethodologicalqualityandconclusions AT gøtzschepeterc industrysupportedmetaanalysescomparedwithmetaanalyseswithnonprofitornosupportdifferencesinmethodologicalqualityandconclusions |